topotecan has been researched along with Leukemia in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (44.44) | 18.2507 |
| 2000's | 12 (44.44) | 29.6817 |
| 2010's | 2 (7.41) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, G; Huang, M; Huang, Y; Li, K; Lu, J; Sheng, C; Wang, T; Wu, S | 1 |
| Fu, LW; He, JH; Huang, ZC; To, KK; Wang, F; Wang, XK; Xu, JH; Ye, S; Zhang, H | 1 |
| Adamson, PC; Berg, S; Blaney, SM; Ingle, AM; Krailo, M; Potter, SL | 1 |
| Giles, FJ | 1 |
| Braylan, R; Chen, SF; Fieniewicz, KJ; Gomez, SP; Kahn, S; Leather, H; Lynch, J; Mainwaring, MG; May, WS; Moreb, J; Reddy, V; Rimsza, LM; Rowe, TC; Weeks, FW; Wingard, JR | 1 |
| Gore, SD; Malek, SN | 1 |
| Kaufmann, SH; Svingen, PA | 1 |
| Kolb, EA; Steinherz, PG | 1 |
| Fu, ZZ; Ma, R; Qiu, HY; Ruan, CG; Sun, AN; Tang, XW; Wu, DP | 1 |
| Pavlidis, N; Pentheroudakis, G | 1 |
| Adjei, AA; Ames, MM; Atherton, P; Erlichman, C; Gojo, I; Greer, J; Karp, JE; Kaufmann, SH; Kottke, TJ; Letendre, L; Litzow, MR; Loegering, DA; Reid, JM; Safgren, S; Sloan, JA; Svingen, PA | 1 |
| Hong, HY; Li, X; Liang, GW; Liu, Y; Long, C; Lu, WL; Ma, X; Ruan, GR; Wang, JC; Yuan, L; Zhang, Q; Zhang, X; Zhang, YT | 1 |
| Hong, HY; Li, X; Liang, GW; Liu, Y; Long, C; Lu, WL; Ruan, GR; Wang, JC; Zhang, Q; Zhang, X; Zhang, YT | 1 |
| Adams, DJ; Giles, F; Jacobsen, TF; Myhren, F; Rizzieri, DA; Sandvold, ML | 1 |
| Donehower, RC; Grochow, LB; Kaufmann, SH; Rowinsky, EK; Slichenmyer, WJ | 1 |
| Adjei, A; Burke, PJ; Cheng, YC; Donehower, RC; Gore, SD; Grochow, LB; Jones, RJ; Kaufmann, SH; Rowinsky, EK | 1 |
| Ellis, AL; Nowak, B; Plunkett, W; Zwelling, LA | 1 |
| Beran, M; Cazenave, L; Ellis, A; Kantarjian, HM; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W; Rios, MB; Zwelling, L | 1 |
| Baker, SD; Evans, WE; Furman, WL; Pratt, CB; Rivera, GK; Stewart, CF | 1 |
| Darzynkiewicz, Z; Feldman, E; Halicka, HD; Seiter, K; Traganos, F | 1 |
| Buckwalter, CA; Burke, PJ; Donehower, RC; Gore, SD; Grochow, LB; Jones, RJ; Kaufmann, SH; Kottke, T; Letendre, L; Rowinsky, EK; Svingen, PA | 1 |
| Armstrong, DK; Cheng, YC; Gore, SD; Kaufmann, SH; Rowinsky, EK; Svingen, PA | 1 |
| Seiter, K | 1 |
| Baker, SD; Bowling, MK; Chen, TL; Donehower, RC; Gore, SD; Kaufmann, SH; Miller, CB; Rowinsky, EK; Sartorius, SE | 1 |
| Beran, M; Cortes, J; Estey, E; Giles, F; Kantarjian, H; Keating, M; Koller, C; O'Brien, S | 1 |
| Kancherla, R; Nair, JS; Seiter, K; Traganos, F; Tse-Dinh, YC | 1 |
| Donehower, RC; Grochow, LB; Hendricks, CB; Kaufmann, SH; Rowinsky, EK | 1 |
4 review(s) available for topotecan and Leukemia
| Article | Year |
|---|---|
Troxacitabine-based therapy of refractory leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Cytosine; Dioxolanes; Humans; Idarubicin; Leukemia; Remission Induction; Topotecan | 2002 |
Management of leptomeningeal malignancy.
Topics: Adenocarcinoma; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Arachnoid Cysts; Carcinoma; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Delayed-Action Preparations; Enzyme Inhibitors; Humans; Injections, Intravenous; Injections, Spinal; Leukemia; Lymphoma; Meningeal Neoplasms; Methotrexate; Palliative Care; Randomized Controlled Trials as Topic; Thiotepa; Topoisomerase I Inhibitors; Topotecan | 2005 |
Factors affecting topotecan sensitivity in human leukemia samples.
Topics: Antineoplastic Agents; Camptothecin; Cell Differentiation; Clinical Trials, Phase I as Topic; Drug Resistance; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Forecasting; Humans; Leukemia; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1996 |
Induction of apoptosis by topotecan: implications for the treatment of leukemia.
Topics: Antineoplastic Agents; Apoptosis; Enzyme Inhibitors; Humans; Leukemia; Topoisomerase I Inhibitors; Topotecan | 1998 |
10 trial(s) available for topotecan and Leukemia
| Article | Year |
|---|---|
Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: a Children's Oncology Group trial (P9962).
Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Injections, Spinal; Leukemia; Male; Meningeal Neoplasms; Neoplasm Recurrence, Local; Survival Analysis; Topoisomerase I Inhibitors; Topotecan; Young Adult | 2012 |
Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; DNA Fragmentation; DNA Topoisomerases, Type II; Enzyme Induction; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Topotecan | 2002 |
A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Dexamethasone; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukemia; Male; Recurrence; Thiotepa; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Carboplatin; Cell Cycle Proteins; Combined Modality Therapy; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; HL-60 Cells; Humans; Immunoblotting; Infusions, Intravenous; Leukemia; Male; Middle Aged; Neoplasm Recurrence, Local; Proliferating Cell Nuclear Antigen; Topotecan; Treatment Outcome | 2005 |
Camptothecin analogues: studies from the Johns Hopkins Oncology Center.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Kidney; Leukemia; Liver; Metabolic Clearance Rate; Neoplasms; Platelet Count; Topoisomerase I Inhibitors; Topotecan | 1994 |
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Camptothecin; Daunorubicin; Drug Administration Schedule; Drug Resistance, Multiple; Female; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia; Male; Middle Aged; Mouth Mucosa; Quinidine; Remission Induction; Stomatitis; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1994 |
Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Camptothecin; DNA; DNA Topoisomerases, Type I; Drug Administration Schedule; Female; Humans; Irinotecan; Leukemia; Male; Middle Aged; Topoisomerase I Inhibitors; Topotecan | 1993 |
Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Infant; Infusions, Intravenous; Leukemia; Male; Metabolic Clearance Rate; Recurrence; Topotecan | 1996 |
A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Bone Marrow; DNA Topoisomerases, Type I; Female; Humans; Leukemia; Male; Middle Aged; Mucous Membrane; Neoplasm Recurrence, Local; Topotecan; Treatment Outcome | 1996 |
Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Humans; Leukemia; Middle Aged; Recurrence; Topotecan; Treatment Outcome | 2000 |
13 other study(ies) available for topotecan and Leukemia
| Article | Year |
|---|---|
Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Leukemia; Structure-Activity Relationship | 2022 |
Afatinib enhances the efficacy of conventional chemotherapeutic agents by eradicating cancer stem-like cells.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; DNA Methylation; Drug Synergism; Humans; Leukemia; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Neoplastic Stem Cells; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Signal Transduction; Topotecan; Xenograft Model Antitumor Assays | 2014 |
Commentary: topoisomerases as targets in acute leukemia: I, II, I plus II or none?
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Leukemia; Neoplasm Proteins; Remission Induction; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome | 2003 |
Immunoblot analysis and band depletion assays.
Topics: Acridines; Antineoplastic Agents; DNA Adducts; DNA Topoisomerases, Type I; Humans; Immunoblotting; K562 Cells; Leukemia; Pyrazoles; Topotecan | 1999 |
[Topotecan-based combined chemotherapy for refractory or relapsed hematologic malignancies].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Female; Humans; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Topotecan | 2003 |
A novel stealth liposomal topotecan with amlodipine: apoptotic effect is associated with deletion of intracellular Ca2+ by amlodipine thus leading to an enhanced antitumor activity in leukemia.
Topics: Amlodipine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Calcium; Caspases; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; HL-60 Cells; Humans; K562 Cells; Leukemia; Liposomes; Microscopy, Confocal; Topotecan | 2006 |
Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.
Topics: Amlodipine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Division; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Leukemia; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 2006 |
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cytarabine; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Hydrazines; Idarubicin; Irinotecan; Leukemia; Lymphoma; Sulfonamides; Topotecan | 2008 |
Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
Topics: Amsacrine; Antineoplastic Agents; Camptothecin; DNA Probes; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Resistance; Etoposide; Humans; Immunoblotting; Leukemia; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 1994 |
Induction of apoptosis by camptothecin and topotecan.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Marrow; Camptothecin; Cell Cycle; Cytarabine; DNA Damage; Enzyme Inhibitors; HL-60 Cells; Humans; Leukemia; Topotecan | 1996 |
Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells.
Topics: Antineoplastic Agents; Camptothecin; DNA Adducts; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance, Neoplasm; Electrophoresis, Polyacrylamide Gel; Enzyme Stability; Humans; Leukemia; Prospective Studies; Topotecan | 1997 |
Action of topoisomerase targeting drugs on non-Hodgkin's lymphoma and leukemia. Correlation of clinical and cell culture studies.
Topics: Acute Disease; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Cytarabine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Isoenzymes; Leukemia; Leukocytes; Lymphoma, Non-Hodgkin; Mitoxantrone; Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2000 |
Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.
Topics: Acute Disease; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Camptothecin; CHO Cells; Cricetinae; DNA Topoisomerases, Type I; DNA, Neoplasm; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Flow Cytometry; Leukemia; Membrane Glycoproteins; Quinidine; Topotecan; Tumor Cells, Cultured | 1992 |